1. |
The Scottish Medicines Consortium (SMC) has rejected two products for use within the Scottish NHS, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
LMWH cost effective for perioperative bridging therapy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
Somatropin provides long-term QOL improvement in GHD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
Counting the costs of MS |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 5-6
&NA;,
Preview
|
|
摘要:
Multiple sclerosis (MS) is a common, neurological autoimmune disease that affects approximately 400 000 individuals in the US alone. Its effects on patients' central nervous systems can be debilitating, and often result in chronic morbidity and disability, which takes a substantial financial toll on society. Several studies presented at the 9th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Arlington, Virginia, US; May 2004] considered the economic burden of MS, and the cost effects associated with drug treatments.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
L. paracasei-33 fortified milk improves QOL in PAR |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
6. |
Mycophenolate mofetil: potential treatment for multiple sclerosis? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
7. |
Looking at the MOSAIC trial: adjuvant oxaliplatin in colon cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
8. |
Rasagiline leads to less time in 'off' state in PD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 9-10
RL Roper,,
Preview
|
|
摘要:
Once-daily rasagiline, an investigational selective and potent monoamine oxidase type B (MAO-B) inhibitor, is superior to placebo and as effective as entacapone in reducing 'off' time in levodopa-treated patients with advanced Parkinson's disease (PD) and motor fluctuations. This result and other data from the multinational, randomised, double-blind LARGO study were presented at the 56th Annual Meeting of the American Academy of Neurology [San Francisco, US; April−May 2004]. In addition, results from an ancillary study of the LARGO study showed that rasagiline significantly improves freezing of gait (FOG) in this patient group."We continue to be excited about the potential for rasagiline to help people living with Parkinson's disease", said Dr Rivka Riven Kreitman, vice president of Innovative R&D with Teva Neuroscience. The results of the ancillary study showed that"rasagiline significantly improved one of the most troublesome and limiting symptoms in advanced PD".
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
9. |
Rofecoxib superior to nabumetone in knee OA |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
10. |
Azithromycin doesn't prevent HIV-1 infection in female sex workers |
|
Inpharma Weekly,
Volume &NA;,
Issue 1441,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|